Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

29.12 -0.58 (-1.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
4 Analysts Have This To Say About Ultragenyx Pharmaceutical
 
Via Benzinga
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83. 
Via Investor's Business Daily
Expert Ratings for Ultragenyx Pharmaceutical
 
Via Benzinga
Analyst Ratings for Ultragenyx Pharmaceutical
 
Via Benzinga
Earnings Outlook For Ultragenyx Pharmaceutical
 
Via Benzinga
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. 
Via Investor's Business Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterol 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate at Investor Conferences in November
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate in the Jefferies London Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
AT&T, Union Pacific, Las Vegas Sands And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 30 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. 
Via Benzinga
Topics Bankruptcy
Stocks Fall As Bond Yields Hit Multi-Year Highs
The major indexes are firmly lower this afternoon, with both the Dow Jones Industrial Average and Nasdaq Composite down triple digits as bond yields rise. 
Via Talk Markets
Topics Bonds Stocks
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.